Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.


Understanding Next Generation Organoids

Understanding Next Generation Organoids
Reported by
Ashlea Morgan

Posted February 10, 2020

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

In the last two decades, remarkable advances in 3D culture technology have made organoids possible. Using embryonic or adult mammalian stem cells, researchers worked to achieve tissue-like mimetics that assemble into a relevant tissue-specific structure, taking on the functional properties of organs. Through careful study of the desired functions of a target organ and the implementation of its microstructure, researchers have created organoids that can serve as platforms for high-throughput, multi-scaled drug screening. Organs-on-chips have also been used to model human organ disease and study organ development. Patient-derived organoids hold promise for personalized medicine because they have the potential to indicate individualized predictions of drug response.

Learn more about recent progress in 3D culture technology, the development of organoid protocols and models, and their application in this summary of our November 12, 2019 symposium.

Symposium Highlights

  • Organoids have been designed to model tissue from almost all of the organs in the body. Lgr5, for example, represents a marker for active epithelial stem cells, including those in the kidney, liver, mammary gland, and stomach epithelium.
  • Organoids that are engineered to take on a structure similar to that found in vivo can model some of the functional aspects of healthy and diseased tissue.
  • Patient-derived organoids can be used to perform drug screening for personalized medicine and to predict drug efficacy, as well as toxicity in clinical trials.
  • Engineering systems of connecting organoids that function in concert allows for the study of complex cellular and organ system-level behavioral phenomena in vitro.
Organoid Technology
Advances in 3D Cell Culture
Organoid Models of Disease and Drug Development